nach oben

Clinical Rheumatology

Erschienen in:

01.06.2013 | Case Based Review

Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review

verfasst von: Soamarat Vilaiyuk, Nongnuch Sirachainan, Suthep Wanitkun, Kwanchai Pirojsakul, Jarin Vaewpanich

Erschienen in: Clinical Rheumatology | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Macrophage activation syndrome (MAS) is a fatal complication in rheumatic diseases. It is characterized by prolonged fever, pancytopenia, and hepatosplenomegaly, which are consequences of uncontrolled macrophage activation. MAS in children is most commonly associated with systemic juvenile idiopathic arthritis. Its association with systemic lupus erythematosus (SLE) is relatively rare, so we report a Thai boy who initially presented with MAS and eventually was diagnosed as having SLE. He also had recurrent MAS during the course of therapy. Hyperferritinemia is one of the abnormal laboratory findings in MAS and it has been used as an inflammatory marker. However, its correlation with disease activity remains unclear. Therefore, a review of literature regarding MAS-associated SLE in children and ferritin level in this disease was carried out.

Sawhney S, Woo P, Murray KJ (2001) Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 85(5):421–426PubMedCrossRef

Behrens EM, Beukelman T, Paessler M, Cron RQ (2007) Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 34(5):1133–1138PubMed

Fukaya S, Yasuda S, Hashimoto T, Oku K, Kataoka H, Horita T et al (2008) Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology (Oxford) 47(11):1686–1691CrossRef

Kwak EL, Larochelle DA, Beaumont C, Torti SV, Torti FM (1995) Role for NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha. J Biol Chem 270(25):15285–15293PubMedCrossRef

Bennett TD, Hayward KN, Farris RW, Ringold S, Wallace CA, Brogan TV (2011) Very high serum ferritin levels are associated with increased mortality and critical care in pediatric patients. Pediatr Crit Care Med 12(6):e233–e236PubMedCrossRef

Stephan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM (1993) Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol 11(4):451–456PubMed

Hadchouel M, Prieur AM, Griscelli C (1985) Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 106(4):561–566PubMedCrossRef

Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124–131PubMedCrossRef

Lambotte O, Khellaf M, Harmouche H, Bader-Meunier B, Manceron V, Goujard C et al (2006) Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome. Medicine(Baltimore) 85(3):169–182

10.

Parodi A, Davi S, Pringe AB, Pistorio A, Ruperto N, Magni-Manzoni S et al (2009) Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum 60(11):3388–3399PubMedCrossRef

11.

Lin TF, Ferlic-Stark LL, Allen CE, Kozinetz CA, McClain KL (2011) Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer 56(1):154–155PubMedCrossRef

12.

Kaito K, Kobayashi M, Katayama T, Otsubo H, Ogasawara Y, Sekita T et al (1997) Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases. Eur J Haematol 59(4):247–253PubMedCrossRef

13.

Emmenegger U, Frey U, Reimers A, Fux C, Semela D, Cottagnoud P et al (2001) Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol 68(1):4–10PubMedCrossRef

14.

Campos LM, Omori CH, Lotito AP, Jesus AA, Porta G, Silva CA (2010) Acute pancreatitis in juvenile systemic lupus erythematosus: a manifestation of macrophage activation syndrome? Lupus 19(14):1654–1658PubMedCrossRef

15.

Takizawa Y, Maruyama J, Setoguchi K (2009) Cyclosporin rapidly diminished a severe lupus-associated macrophage activation syndrome refractory to pulsed methylprednisolone and intravenous immunoglobulin. Scand J Rheumatol 38(6):492–494PubMedCrossRef

16.

Yeap ST, Sheen JM, Kuo HC, Hwang KP, Yang KD, Yu HR (2008) Macrophage activation syndrome as initial presentation of systemic lupus erythematosus. Pediatr Neonatol 49(2):39–42PubMedCrossRef

17.

Iagaru N, Oraseanu D, Rusu F, Luminos M, Draganescu A, Ghita A (2010) Macrophage activation syndrome in two girls with systemic lupus erythematosus. Ther Pharmacol Clin Toxicol 15:231–237

18.

Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED (2006) Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr 148(5):683–686PubMedCrossRef

19.

Kwon CM, Jung YW, Yun DY, Kim HD, Cho HS, Hong YH, Choi JH, Lee CK (2008) A case of pericarditis with hemophagocytic syndrome, cytomegalovirus infection and systemic lupus erythematosus. Rheumatol Int 28(3):271–273PubMedCrossRef

20.

Botelho C, Ferrer F, Francisco L, Maia P, Mendes T, Carreira A (2010) Acute lupus hemophagocytic syndrome: report of a case. Nefrologia 30(2):247–251PubMed

21.

McCann LJ, Hasson N, Pilkington CA (2006) Macrophage activation syndrome as an early presentation of lupus. J Rheumatol 33(2):438–440PubMed

22.

Kim JM, Kwok SK, Ju JH, Park KS, Park GS, Kim HY, Park SH (2010) Macrophage activation syndrome resistant to medical therapy in a patient with systemic lupus erythematosus and its remission with splenectomy. Rheumatol Int 33(3):767–771. doi:10.1007/s00296-010-1654-4 PubMedCrossRef

23.

Ideguchi H, Ohono S, Takase K, Hattori H, Kirino Y, Takeno M et al (2007) Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab. Rheumatology 46(10):1621–1622PubMedCrossRef

24.

You CR, Kim HR, Yoon CH, Lee SH, Park SH, Kim HY (2006) Macrophage activation syndrome in juvenile rheumatoid arthritis successfully treated with cyclosporine A: a case report. J Korean Med Sci 21(6):1124–1127PubMedCrossRef

25.

Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM (1996) Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 129(5):750–754PubMedCrossRef

26.

Ravelli A, De Benedetti F, Viola S, Martini A (1996) Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 128(2):275–278PubMedCrossRef

Titel: Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review
verfasst von: Soamarat Vilaiyuk
Nongnuch Sirachainan
Suthep Wanitkun
Kwanchai Pirojsakul
Jarin Vaewpanich
Publikationsdatum: 01.06.2013
Verlag: Springer-Verlag
Erschienen in: Clinical Rheumatology / Ausgabe 6/2013
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-013-2227-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

Organ involvement in Argentinian systemic sclerosis patients with “late” pattern as compared to patients with “early/active” pattern by nailfold capillaroscopy

Factors associated with gout in South Koreans: analysis using the National Health Insurance Corporation and the National Health Screening Exam databases

Systemic lupus erythematosus-related pancreatitis in children

Aggrecanases in the human synovial fluid at different stages of osteoarthritis

Regional migratory osteoporosis and transient osteoporosis of the hip: are they all the same?

Idiopathic retroperitoneal fibrosis: a clinicopathological study in 24 Spanish cases